Literature DB >> 6661235

The metabolic defect of methionine dependence occurs frequently in human tumor cell lines.

J O Mecham, D Rowitch, C D Wallace, P H Stern, R M Hoffman.   

Abstract

Methionine dependence is the inability of cells to grow when methionine (Met) is replaced by its immediate precursor homocysteine (Hcy) in the culture medium (Met-Hcy+ medium). All normal unestablished cell strains tested to date have been shown to be methionine-independent and thus grow almost as well in Met-Hcy+ medium as they do in Met+-Hcy-medium. Results presented here indicate that out of 23 cell lines derived from diverse types of human tumors, 11 do not grow at all in Met-Hcy+ medium and are absolutely methionine-dependent and 3 grow only slightly in this medium. Many of the tumor cell lines tested have little else in common other than the fact that they are methionine-dependent. The high frequency of occurrence of methionine dependence in diverse types of human tumor cells indicates that methionine dependence may be an important aspect of oncogenic transformation and therapeutically exploitable.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661235     DOI: 10.1016/0006-291x(83)91218-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  51 in total

1.  Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.

Authors:  Elena Strekalova; Dmitry Malin; David M Good; Vincent L Cryns
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.

Authors:  Kei Kawaguchi; Kentaro Miyake; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Thinzar M Lwin; Takashi Higuchi; Tasuku Kiyuna; Masuyo Miyake; Hiromichi Oshiro; Michael Bouvet; Michiaki Unno; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-05-21       Impact factor: 4.534

Review 3.  The wayward methyl group and the cascade to cancer.

Authors:  Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-03-20       Impact factor: 4.534

4.  S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.

Authors:  Elena Strekalova; Dmitry Malin; Erin M M Weisenhorn; Jason D Russell; Dominik Hoelper; Aayushi Jain; Joshua J Coon; Peter W Lewis; Vincent L Cryns
Journal:  Breast Cancer Res Treat       Date:  2019-02-02       Impact factor: 4.872

5.  Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts.

Authors:  V S Pokrovsky; N Yu Anisimova; D Zh Davydov; S V Bazhenov; N V Bulushova; G B Zavilgelsky; V Y Kotova; I V Manukhov
Journal:  Invest New Drugs       Date:  2018-06-15       Impact factor: 3.850

6.  Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.

Authors:  Evan C Lien; Laura Ghisolfi; Renee C Geck; John M Asara; Alex Toker
Journal:  Sci Signal       Date:  2017-12-19       Impact factor: 8.192

7.  Unchecked DNA synthesis and blocked cell division induced by methionine deprivation in a human prostate cancer cell line.

Authors:  H Y Guo; R M Hoffman; H Herrera
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-05       Impact factor: 2.416

Review 8.  11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.

Authors:  Tarun Singhal; Tanjore K Narayanan; Viney Jain; Jogeshwar Mukherjee; Joseph Mantil
Journal:  Mol Imaging Biol       Date:  2007-10-24       Impact factor: 3.488

9.  Downregulation of Cdc6 and pre-replication complexes in response to methionine stress in breast cancer cells.

Authors:  Keith Booher; Da-Wei Lin; Stacey L Borrego; Peter Kaiser
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

10.  Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Shukuan Li; Qinghong Han; Yuying Tan; Ming Zhao; Yunfeng Li; Scott D Nelson; Sarah M Dry; Arun S Singh; Irmina A Elliott; Tara A Russell; Mark A Eckardt; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.